# Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents for Diffuse Long Coronary Artery Disease

> **NCT02831205** · PHASE4 · TERMINATED · sponsor: **Duk-Woo Park, MD** · enrollment: 800 (estimated)

## Conditions studied

- Percutaneous Transluminal Coronary Angioplasty

## Interventions

- **DEVICE:** everolimus-eluting bioresorbable vascular (Absorb) scaffold
- **DEVICE:** everolimus-eluting cobalt-chromium (Xience) stent

## Key facts

- **NCT ID:** NCT02831205
- **Lead sponsor:** Duk-Woo Park, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-07
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 800 (ESTIMATED)
- **Why stopped:** Due to current BVS safety issue
- **Last updated:** 2017-12-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02831205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02831205, "Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents for Diffuse Long Coronary Artery Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02831205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*